Michel Koole

List of Publications by Year
in descending order

116 papers	3,284 citations	126907 33 h-index	182427 51 g-index
121 all docs	121 docs citations	121 times ranked	4202 citing authors

#	Article	IF	Citations
1	Prospective comparison of simultaneous [68Ga]Ga-PSMA-11 PET/MR versus PET/CT in patients with biochemically recurrent prostate cancer. European Radiology, 2022, 32, 901-911.	4.5	11
2	Regional glucose metabolic decreases with ageing are associated with microstructural white matter changes: a simultaneous PET/MR study. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 664-680.	6.4	10
3	Cross-Modal Distillation to Improve MRI-Based Brain Tumor Segmentation With Missing MRI Sequences. IEEE Transactions on Biomedical Engineering, 2022, 69, 2153-2164.	4.2	15
4	Synaptic Damage and Its Clinical Correlates in People With Early Huntington Disease. Neurology, 2022, 98, .	1.1	26
5	The PET tracer [11C]MK-6884 quantifies M4 muscarinic receptor in rhesus monkeys and patients with Alzheimer's disease. Science Translational Medicine, 2022, 14, eabg3684.	12.4	10
6	Impact of meningeal uptake and partial volume correction techniques on [18F]MK-6240 binding in aMCI patients and healthy controls. Journal of Cerebral Blood Flow and Metabolism, 2022, 42, 1236-1246.	4.3	10
7	Cannabinoid receptor availability modulates the magnitude of dopamine release in vivo in the human reward system: A preliminary multitracer positron emission tomography study. Addiction Biology, 2022, 27, e13167.	2.6	2
8	Spatial decrease of synaptic density in amnestic mild cognitive impairment follows the tau build-up pattern. Molecular Psychiatry, 2022, 27, 4244-4251.	7.9	15
9	Clinical validation of the novel HDAC6 radiotracer [18F]EKZ-001 in the human brain. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 596-611.	6.4	16
10	In vivo synaptic density relates to glucose metabolism at rest in healthy subjects, but is strongly modulated by regional differences. Journal of Cerebral Blood Flow and Metabolism, 2021, 41, 0271678X2098150.	4.3	21
11	Quantitative Whole-Body Diffusion-weighted MRI after One Treatment Cycle for Aggressive Non-Hodgkin Lymphoma Is an Independent Prognostic Factor of Outcome. Radiology Imaging Cancer, 2021, 3, e200061.	1.6	3
12	Human biodistribution and dosimetry of [11C]-UCB-J, a PET radiotracer for imaging synaptic density. EJNMMI Physics, 2021, 8, 37.	2.7	3
13	Synaptic density in healthy human aging is not influenced by age or sex: a 11C-UCB-J PET study. NeuroImage, 2021, 232, 117877.	4.2	31
14	A dual-time-window protocol to reduce acquisition time of dynamic tau PET imaging using [18F]MK-6240. EJNMMI Research, 2021, 11, 49.	2.5	9
15	Minimally invasive quantification of cerebral P2X7R occupancy using dynamic [18F]JNJ-64413739 PET and MRA-driven image derived input function. Scientific Reports, 2021, 11, 16172.	3.3	6
16	Cognitive Decline Assessment: A Review From Medical Imaging Perspective. Frontiers in Aging Neuroscience, 2021, 13, 704661.	3.4	6
17	Lower regional gray matter volume in the absence of higher cortical amyloid burden in late-life depression. Scientific Reports, 2021, 11, 15981.	3.3	13
18	Synthetic Pept-Ins as a Generic Amyloid-Like Aggregation-Based Platform for In Vivo PET Imaging of Intracellular Targets. Bioconjugate Chemistry, 2021, 32, 2052-2064.	3.6	4

#	Article	IF	Citations
19	Changes in synaptic density in the subacute phase after ischemic stroke: A 11C-UCB-J PET/MR study. Journal of Cerebral Blood Flow and Metabolism, 2021, , 0271678X2110477.	4.3	12
20	Preclinical Evaluation of [11C]YC-72-AB85 for *In Vivo* Visualization of Heat Shock Protein 90 in Brain and Cancer with Positron Emission Tomography. ACS Chemical Neuroscience, 2021, 12, 3915-3927.	3.5	4
21	Twelve-Week Yoga vs. Aerobic Cycling Initiation in Sedentary Healthy Subjects: A Behavioral and Multiparametric Interventional PET/MR Study. Frontiers in Psychiatry, 2021, 12, 739356.	2.6	3
22	The Effect of Aging on Brain Glucose Metabolic Connectivity Revealed by [18F]FDG PET-MR and Individual Brain Networks. Frontiers in Aging Neuroscience, 2021, 13, 798410.	3.4	2
23	Glucose metabolism changes in cerebellar tonsils as an early predictor of cognitive decline. Alzheimer's and Dementia, 2021, 17, .	0.8	0
24	Preclinical Safety Evaluation and Human Dosimetry of [18F]MK-6240, a Novel PET Tracer for Imaging Neurofibrillary Tangles. Molecular Imaging and Biology, 2020, 22, 173-180.	2.6	21
25	Validation of Parametric Methods for [11C]UCB-J PET Imaging Using Subcortical White Matter as Reference Tissue. Molecular Imaging and Biology, 2020, 22, 444-452.	2.6	28
26	TSPO Versus P2X7 as a Target for Neuroinflammation: An In Vitro and In Vivo Study. Journal of Nuclear Medicine, 2020, 61, 604-607.	5.0	42
27	Inflammation-Based Index and 68Ga-DOTATOC PET–Derived Uptake and Volumetric Parameters Predict Outcome in Neuroendocrine Tumor Patients Treated with 90Y-DOTATOC. Journal of Nuclear Medicine, 2020, 61, 1014-1020.	5.0	28
28	Quantification and discriminative power of 18F-FE-PE2I PET in patients with Parkinson's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 1913-1926.	6.4	24
29	Monte Carlo Simulations of the GE Signa PET/MR for Different Radioisotopes. Frontiers in Physiology, 2020, 11, 525575.	2.8	7
30	Loss of Presynaptic Terminal Integrity in the Substantia Nigra in Early Parkinson's Disease. Movement Disorders, 2020, 35, 1977-1986.	3.9	52
31	Regional distribution of amyloid deposition and grey matter atrophy in late-life depression. Alzheimer's and Dementia, 2020, 16, e041564.	0.8	0
32	Use of Multimodal Imaging and Clinical Biomarkers in Presymptomatic Carriers of *C9orf72* Repeat Expansion. JAMA Neurology, 2020, 77, 1008.	9.0	45
33	In vivo synaptic density loss is related to tau deposition in amnestic mild cognitive impairment. Neurology, 2020, 95, e545-e553.	1.1	56
34	Moving Toward Multicenter Therapeutic Trials in Amyotrophic Lateral Sclerosis: Feasibility of Data Pooling Using Different Translocator Protein PET Radioligands. Journal of Nuclear Medicine, 2020, 61, 1621-1627.	5.0	22
35	Translation of HDAC6 PET Imaging Using [18F]EKZ-001–cGMP Production and Measurement of HDAC6 Target Occupancy in Nonhuman Primates. ACS Chemical Neuroscience, 2020, 11, 1093-1101.	3.5	26
36	[18F]AlF-NOTA-octreotide PET imaging: biodistribution, dosimetry and first comparison with [68Ga]Ga-DOTATATE in neuroendocrine tumour patients. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 3033-3046.	6.4	59

#	Article	IF	Citations
37	Combined brain and spinal FDG PET allows differentiation between ALS and ALS mimics. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2681-2690.	6.4	15
38	Targeted alpha therapy: a critical review of translational dosimetry research with emphasis on actinium-225. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2020, 64, 265-277.	0.7	7
39	Quantifying SV2A density and drug occupancy in the human brain using [11C]UCB-J PET imaging and subcortical white matter as reference tissue. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 396-406.	6.4	72
40	Al18F-NOTA-octreotide: first comparison with 68Ga-DOTATATE in a neuroendocrine tumour patient. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 2398-2399.	6.4	30
41	ICâ€Pâ€150: [Câ€11]MKâ€6884 PET: CHARACTERIZING BRAIN M4 RECEPTORS IN HEALTHY ELDERLY VOLUNTEERS AND ACETYLCHOLINESTERASE INHIBITORSâ€TREATED AD PATIENTS. Alzheimer's and Dementia, 2019, 15, P121.	0.8	3
42	Identifying a glucose metabolic brain pattern in an adeno-associated viral vector based rat model for Parkinsonâ€™s disease using 18F-FDG PET imaging. Scientific Reports, 2019, 9, 12368.	3.3	5
43	[11C]JNJ54173717, a novel P2X7 receptor radioligand as marker for neuroinflammation: human biodistribution, dosimetry, brain kinetic modelling and quantification of brain P2X7 receptors in patients with Parkinsonâ€™s disease and healthy volunteers. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 2051-2064.	6.4	55
44	Local pulmonary drug delivery in the preterm rabbit: feasibility and efficacy of daily intratracheal injections. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2019, 316, L589-L597.	2.9	17
45	Convolutional Neural Networks for Brain Tumor Segmentation Using Different Sets of MRI Sequences. , 2019, , .		8
46	Regional Accuracy of ZTE-Based Attenuation Correction in Static [18F]FDG and Dynamic [18F]PE2I Brain PET/MR. Frontiers in Physics, 2019, 7, .	2.1	38
47	Preclinical evaluation of [^{18}F]MA3: a CB$_2$ receptor agonist radiotracer for PET. British Journal of Pharmacology, 2019, 176, 1481-1491.	5.4	26
48	^{18}F-JNJ-64413739, a Novel PET Ligand for the P2X7 Ion Channel: Radiation Dosimetry, Kinetic Modeling, Test-Retest Variability, and Occupancy of the P2X7 Antagonist JNJ-54175446. Journal of Nuclear Medicine, 2019, 60, 683-690.	5.0	63
49	Increased Expression of Translocator Protein (TSPO) Marks Pro-inflammatory Microglia but Does Not Predict Neurodegeneration. Molecular Imaging and Biology, 2018, 20, 94-102.	2.6	88
50	Parametric Imaging of [11C]Flumazenil Binding in the Rat Brain. Molecular Imaging and Biology, 2018, 20, 114-123.	2.6	5
51	^{68}Ga-NOTA-Functionalized Ubiquicidin: Cytotoxicity, Biodistribution, Radiation Dosimetry, and First-in-Human PET/CT Imaging of Infections. Journal of Nuclear Medicine, 2018, 59, 334-339.	5.0	44
52	Glucose metabolic brain patterns to discriminate amyotrophic lateral sclerosis from Parkinson plus syndromes. EJNMMI Research, 2018, 8, 110.	2.5	7
53	Volume-of-interest-based supervised cluster analysis for pseudo-reference region selection in [18F]DPA-714 PET imaging of the rat brain. EJNMMI Research, 2018, 8, 112.	2.5	4
54	An approach for a reconstruction-derived whole-blood arterial input function (RDIF) in PET/MRI. , 2018, , .		0

#	Article	IF	Citations
55	Single-word comprehension deficits in the nonfluent variant of primary progressive aphasia. Alzheimer's Research and Therapy, 2018, 10, 68.	6.2	16
56	Distinct [18F]THK5351 binding patterns in primary progressive aphasia variants. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 2342-2357.	6.4	16
57	Positron emission tomography imaging of cerebral glucose metabolism and type 1 cannabinoid receptor availability during temporal lobe epileptogenesis in the amygdala kindling model in rhesus monkeys. Epilepsia, 2018, 59, 959-970.	5.1	17
58	Striatal phosphodiesterase 10A availability is altered secondary to chronic changes in dopamine neurotransmission. EJNMMI Radiopharmacy and Chemistry, 2017, 1, 3.	3.9	13
59	InÂvivo evidence for long-term vascular remodeling resulting from chronic cerebral hypoperfusion in mice. Journal of Cerebral Blood Flow and Metabolism, 2017, 37, 726-739.	4.3	20
60	Asymmetric Amyloid Deposition in the Brain Following Unilateral Electroconvulsive Therapy. Biological Psychiatry, 2017, 81, e11-e13.	1.3	4
61	Dual time-point imaging for post-dose binding potential estimation applied to a [^{11}C]raclopride PET dose occupancy study. Journal of Cerebral Blood Flow and Metabolism, 2017, 37, 866-876.	4.3	2
62	Preclinical Evaluation of ^{18}F-JNJ64349311, a Novel PET Tracer for Tau Imaging. Journal of Nuclear Medicine, 2017, 58, 975-981.	5.0	72
63	Pharmacokinetic modeling of [11C]flumazenil kinetics in the rat brain. EJNMMI Research, 2017, 7, 17.	2.5	7
64	Dual time point method for the quantification of irreversible tracer kinetics: A reference tissue approach applied to [18F]-FDOPA brain PET. Journal of Cerebral Blood Flow and Metabolism, 2017, 37, 3124-3134.	4.3	3
65	Brain PET imaging of phosphodiesterase 10A in progressive supranuclear palsy and Parkinson's disease. Movement Disorders, 2017, 32, 943-945.	3.9	9
66	Pretargeted PET Imaging Using a Bioorthogonal ^{18}F-Labeled *trans*-Cyclooctene in an Ovarian Carcinoma Model. Bioconjugate Chemistry, 2017, 28, 2915-2920.	3.6	38
67	[123I]FP-CIT ENC-DAT normal database: the impact of the reconstruction and quantification methods. EJNMMI Physics, 2017, 4, 8.	2.7	46
68	Preclinical Evaluation and Quantification of 18F-Fluoroethyl and 18F-Fluoropropyl Analogs of SCH442416 as Radioligands for PET Imaging of the Adenosine A2A Receptor in Rat Brain. Journal of Nuclear Medicine, 2017, 58, 466-472.	5.0	18
69	What We Observe In Vivo Is Not Always What We See In Vitro: Development and Validation of 11C-JNJ-42491293, A Novel Radioligand for mGluR2. Journal of Nuclear Medicine, 2017, 58, 110-116.	5.0	31
70	Micro-flow photosynthesis of new dienophiles for inverse-electron-demand Dielsâ€"Alder reactions. Potential applications for pretargeted in vivo PET imaging. Chemical Science, 2017, 8, 1251-1258.	7.4	37
71	Synthesis and preclinical evaluation of [11 C]MA-PB-1 for inÂvivo imaging of brain monoacylglycerol lipase (MAGL). European Journal of Medicinal Chemistry, 2017, 136, 104-113.	5.5	23
72	Total Body Metabolic Tumor Response in ALK Positive Non-Small Cell Lung Cancer Patients Treated with ALK Inhibition. PLoS ONE, 2016, 11, e0149955.	2.5	11

#	Article	IF	Citations
73	Kinetic modeling and long‑term test‑retest reproducibility of the mGluR5 PET tracer ^{18}F‑FPEB in human brain. Synapse, 2016, 70, 153-162.	1.2	18
74	Quantification of TSPO overexpression in a rat model of local neuroinflammation induced by intracerebral injection of LPS by the use of [18F]DPA-714 PET. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 163-172.	6.4	23
75	[18F]JNJ42259152 binding to phosphodiesterase 10A, a key regulator of medium spiny neuron excitability, is altered in the presence of cyclic AMP. Journal of Neurochemistry, 2016, 139, 897-906.	3.9	14
76	Preclinical Evaluation of a P2X7 Receptor–Selective Radiotracer: PET Studies in a Rat Model with Local Overexpression of the Human P2X7 Receptor and in Nonhuman Primates. Journal of Nuclear Medicine, 2016, 57, 1436-1441.	5.0	77
77	Characterization of the novel GlyT1 PET tracer [^{18}F]MK‑6577 in humans. Synapse, 2015, 69, 33-40.	1.2	17
78	A Standardized Method for the Construction of Tracer Specific PET and SPECT Rat Brain Templates: Validation and Implementation of a Toolbox. PLoS ONE, 2015, 10, e0122363.	2.5	52
79	Low-dose CT-derived attenuation scan: One acquisition, more applications?. Journal of Nuclear Cardiology, 2015, 22, 429-430.	2.1	0
80	Imaging of cardiac and renal perfusion in a rat model with 13N–NH3 micro-PET. International Journal of Cardiovascular Imaging, 2015, 31, 213-219.	1.5	6
81	Feasibility of [18F]-RGD for ex vivo imaging of atherosclerosis in detection of $\alpha v\beta 3$ integrin expression. Journal of Nuclear Cardiology, 2015, 22, 1179-1186.	2.1	32
82	Preclinical Evaluation and Quantification of ^{18}F-FPEB as a Radioligand for PET Imaging of the Metabotropic Glutamate Receptor 5. Journal of Nuclear Medicine, 2015, 56, 1954-1959.	5.0	21
83	Endothelial Msx1 transduces hemodynamic changes into an arteriogenic remodeling response. Journal of Cell Biology, 2015, 210, 1239-1256.	5.2	17
84	Abstract OT2-1-10: RAD1901, a novel tissue-selective estrogen receptor degrader (SERD) demonstrates estrogen receptor engagement in a phase 1 clinical study. , 2015, , .		3
85	Positron Emission Tomography (PET) Quantification of GABAA Receptors in the Brain of Fragile X Patients. PLoS ONE, 2015, 10, e0131486.	2.5	52
86	Bone scintigraphy with ^{99m}technetium-hydroxymethylene diphosphonate allows early diagnosis of cardiac involvement in patients with transthyretin-derived systemic amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2014, 21, 35-44.	3.0	129
87	Biodistribution and radiation dosimetry of radioiodinated hypericin as a cancer therapeutic. International Journal of Oncology, 2014, 44, 819-829.	3.3	11
88	Three-dimensional rotational angiography fused with multimodal imaging modalities for targeted endomyocardial injections in the ischaemic heart. European Heart Journal Cardiovascular Imaging, 2014, 15, 900-907.	1.2	10
89	11C-MK-8278 PET as a Tool for Pharmacodynamic Brain Occupancy of Histamine 3 Receptor Inverse Agonists. Journal of Nuclear Medicine, 2014, 55, 65-72.	5.0	23
90	Synthesis and biological evaluation of carbon-11 and fluorine-18 labeled tracers for in vivo visualization of PDE10A. Nuclear Medicine and Biology, 2014, 41, 695-704.	0.6	15

#	ARTICLE	IF	CITATIONS
91	PET Quantification in Neuropsychiatry. , 2014, , 15-44.		0
92	Evaluation of androgen-induced effects on the uptake of [18F]FDG, [11C]choline and [11C]acetate in an androgen-sensitive and androgen-independent prostate cancer xenograft model. EJNMMI Research, 2013, 3, 31.	2.5	13
93	Transient changes in the endocannabinoid system after acute and chronic ethanol exposure and abstinence in the rat: a combined PET and microdialysis study. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 1582-1594.	6.4	41
94	Human biodistribution and dosimetry of 18F-JNJ42259152, a radioligand for phosphodiesterase 10A imaging. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 254-261.	6.4	36
95	Whole-Body Biodistribution and Radiation Dosimetry of the Cannabinoid Type 2 Receptor Ligand [11C]-NE40 in Healthy Subjects. Molecular Imaging and Biology, 2013, 15, 384-390.	2.6	64
96	Fluoro-D-glucose-micro positron emission tomography as a diagnostic tool to confirm brain death in a murine donor lung injury model. Journal of Surgical Research, 2013, 180, 343-348.	1.6	3
97	Quantification of ^{18}F-JNJ-42259152, a Novel Phosphodiesterase 10A PET Tracer: Kinetic Modeling and Test–Retest Study in Human Brain. Journal of Nuclear Medicine, 2013, 54, 1285-1293.	5.0	43
98	Construction and Evaluation of Quantitative Small-Animal PET Probabilistic Atlases for [18F]FDG and [18F]FECT Functional Mapping of the Mouse Brain. PLoS ONE, 2013, 8, e65286.	2.5	16
99	Micro-Positron Emission Tomography Imaging of Rat Brain Metabolism during Expression of Contextual Conditioning. Journal of Neuroscience, 2012, 32, 254-263.	3.6	38
100	Optimized In Vivo Detection of Dopamine Release Using ^{18}F-Fallypride PET. Journal of Nuclear Medicine, 2012, 53, 1565-1572.	5.0	49
101	Proposal for the standardisation of multi-centre trials in nuclear medicine imaging: prerequisites for a European 123I-FP-CIT SPECT database. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 188-197.	6.4	48
102	Calibration of gamma camera systems for a multicentre European 123I-FP-CIT SPECT normal database. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 1529-1540.	6.4	73
103	Preclinical Evaluation of ^{18}F-JNJ41510417 as a Radioligand for PET Imaging of Phosphodiesterase-10A in the Brain. Journal of Nuclear Medicine, 2010, 51, 1584-1591.	5.0	64
104	[18F]JNJ41510417 a potential PET radioligand for imaging phosphodiesterase-10A in the brain. NeuroImage, 2010, 52, S15.	4.2	0
105	Whole-Body Biodistribution and Radiation Dosimetry of ^{18}F-GE067: A Radioligand for In Vivo Brain Amyloid Imaging. Journal of Nuclear Medicine, 2009, 50, 818-822.	5.0	200
106	Phase 1 Study of the Pittsburgh Compound B Derivative ^{18}F-Flutemetamol in Healthy Volunteers and Patients with Probable Alzheimer Disease. Journal of Nuclear Medicine, 2009, 50, 1251-1259.	5.0	273
107	Whole-Body Biodistribution and Radiation Dosimetry of the Human Cannabinoid Type-1 Receptor Ligand ^{18}F-MK-9470 in Healthy Subjects. Journal of Nuclear Medicine, 2008, 49, 439-445.	5.0	38
108	The geometric transfer function for a slat collimator mounted on a strip detector. IEEE Transactions on Nuclear Science, 2005, 52, 708-713.	2.0	8

#	Article	IF	Citations
109	Transmission imaging with a moving point source: influence of crystal thickness and collimator type. IEEE Transactions on Nuclear Science, 2005, 52, 166-173.	2.0	2
110	Study of the quantification of FBP SPECT images with a correction for partial volume effects. IEEE Transactions on Nuclear Science, 2002, 49, 69-73.	2.0	4
111	Influence of detector thickness on resolution in three-headed gamma camera PET. IEEE Transactions on Nuclear Science, 2002, 49, 98-103.	2.0	3
112	Experimental Performance Assessment of SPM for SPECT Neuroactivation Studies Using a Subresolution Sandwich Phantom Design. NeuroImage, 2002, 16, 200-216.	4.2	40
113	Non-invasive methods for absolute cerebral blood flow measurement using 99mTc-ECD: a study in healthy volunteers. European Journal of Nuclear Medicine and Molecular Imaging, 2001, 28, 862-872.	2.1	25
114	99mTc-ECD brain perfusion SPET: variability, asymmetry and effects of age and gender in healthy adults. European Journal of Nuclear Medicine and Molecular Imaging, 2001, 28, 873-887.	2.1	108
115	Non-uniform versus uniform attenuation correction in brain perfusion SPET of healthy volunteers. European Journal of Nuclear Medicine and Molecular Imaging, 2001, 28, 90-98.	2.1	30
116	Transfer of normal 99mTc-ECD brain SPET databases between different gamma cameras. European Journal of Nuclear Medicine and Molecular Imaging, 2001, 28, 435-449.	2.1	33